First and only alternative for patients with hypersensitivity to standard-of-care treatment with E. coli-derived pegaspargase Langhorne, PA and Oxford, UK – 18 November 2011 – EUSA Pharma, a …
FDA Continues BLA Review for EUSA Pharma’s ERWINAZETM
Langhorne, PA and Oxford, UK – 3 August 2011 EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has …
F.D.A. Extends Priority Review of B.L.A. for EUSA Pharma’s ERWINAZETM By 90 Days
Langhorne, PA and Oxford, UK – 4 May 2011 Langhorne, PA and Oxford, UK – May 4, 2011 – EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and …